GTX (GTXI) Competitors

GTX (NASDAQ:GTXI) and Merrimack Pharmaceuticals (NASDAQ:MACK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk.

Does the MarketBeat Community believe in GTXI or MACK?

Merrimack Pharmaceuticals received 85 more outperform votes than GTX when rated by MarketBeat users. However, 73.60% of users gave GTX an outperform vote while only 67.00% of users gave Merrimack Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
GTX	Outperform Votes 315 73.60%	Underperform Votes 113 26.40%
Merrimack Pharmaceuticals	Outperform Votes 400 67.00%	Underperform Votes 197 33.00%

Do insiders & institutionals have more ownership in GTXI or MACK?

9.5% of GTX shares are held by institutional investors. Comparatively, 64.0% of Merrimack Pharmaceuticals shares are held by institutional investors. 40.9% of GTX shares are held by company insiders. Comparatively, 28.9% of Merrimack Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media prefer GTXI or MACK?

In the previous week, GTX had 4 more articles in the media than Merrimack Pharmaceuticals. MarketBeat recorded 5 mentions for GTX and 1 mentions for Merrimack Pharmaceuticals. GTX's average media sentiment score of 0.00 beat Merrimack Pharmaceuticals' score of -0.36 indicating that GTX is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GTX	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Merrimack Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer GTXI or MACK?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GTX	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Merrimack Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Which has preferable earnings and valuation, GTXI or MACK?

Merrimack Pharmaceuticals is trading at a lower price-to-earnings ratio than GTX, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GTX	N/A	N/A	-$38.42M	-$1.65	-5.37
Merrimack Pharmaceuticals	N/A	N/A	-$1.18M	-$0.08	-184.00

Which has more risk & volatility, GTXI or MACK?

GTX has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Comparatively, Merrimack Pharmaceuticals has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.

Is GTXI or MACK more profitable?

Merrimack Pharmaceuticals' return on equity of -6.24% beat GTX's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GTX	N/A	-104.19%	-86.42%
Merrimack Pharmaceuticals	N/A	-6.24%	-6.09%

Summary

GTX and Merrimack Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.